calendar

3 catalysts · 18,987 approval · 5,159 phase readout · 5,000 device 510k · 4,728 grant · 2,487 8k filing · 2,000 device pma

★ save view ↓export CSV

next 91 dayslessmore

MonWedFri

view

agenda month

hide past →

sort

soonest latest type sponsor alpha

type: phase 1 results×clear all

type

approval18,987
phase readout5,159
device 510k5,000
grant4,728
8k filing2,487
device pma2,000

device recall

2,000

recall1,126

device adverse event1,000

pdufa319

therapy area

Women's Health2
Infectious Disease1
Oncology1

Week of Apr 20, 2026

›Apr 24, 2026phase 1 results97d agoWroclaw Medical University — viral-specific T-cells (Phase I Trial Results)viral-specific T-cells

Therapy area: Hematological Disorders, Infectious Disease, Oncology. Indication: Aplastic Anemia, Cytomegalovirus (HHV-5) Infections, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Refractory Acute Myeloid Leukemia, Viral Infections

full page →viral-specific T-cells →source: globaldata

›Apr 24, 2026phase 1 results97d agoMedicus Pharma Ltd — teverelix (Phase I Trial Results)teverelix

Therapy area: Women's Health. Indication: Endometriosis

full page →teverelix →source: globaldata

›Apr 24, 2026phase 1 results97d agoMedicus Pharma Ltd — teverelix (Phase I Trial Results)teverelix

Therapy area: Women's Health. Indication: Endometriosis

full page →teverelix →source: globaldata

$MDCX0.3842+2.59%